Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer
about
Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesMetformin induces cell cycle arrest at the G1 phase through E2F8 suppression in lung cancer cells.Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10.
P2860
Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Combinational Therapy Enhances ...... Target Small Cell Lung Cancer
@ast
Combinational Therapy Enhances ...... Target Small Cell Lung Cancer
@en
Combinational Therapy Enhances ...... Target Small Cell Lung Cancer
@nl
type
label
Combinational Therapy Enhances ...... Target Small Cell Lung Cancer
@ast
Combinational Therapy Enhances ...... Target Small Cell Lung Cancer
@en
Combinational Therapy Enhances ...... Target Small Cell Lung Cancer
@nl
prefLabel
Combinational Therapy Enhances ...... Target Small Cell Lung Cancer
@ast
Combinational Therapy Enhances ...... Target Small Cell Lung Cancer
@en
Combinational Therapy Enhances ...... Target Small Cell Lung Cancer
@nl
P2093
P2860
P1433
P1476
Combinational Therapy Enhances ...... Target Small Cell Lung Cancer
@en
P2093
Hongchang Shen
Hongxin Cao
Linhai Zhu
P2860
P304
P356
10.1371/JOURNAL.PONE.0135844
P407
P577
2015-01-01T00:00:00Z